Trial Profile
Open-Label, Imaging Study of Human Corticotropin-Releasing Factor (hCRF) for The Reduction of Peritumoural Brain Oedema (PBE) in Patients With Primary Malignant or Metastatic Brain Tumours
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Corticorelin (Primary)
- Indications Brain oedema
- Focus Therapeutic Use
- 12 Apr 2014 New trial record
- 08 Jan 2009
- 28 Sep 2008